



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Product Information

Description:	Recombinant human ST2, also known IL1RL1 (interleukin 1 receptor like 1), transcript variant 1, encompassing amino acids 19-328. This construct contains at the C-terminus a Factor Xa site, followed by the Fc domain of a human IgG1, an Avi-Tag™. The recombinant protein was affinity purified.
Background:	IL-33 is a cytokine of the IL-1 family that is released in response to external triggers, such as trauma, allergen exposure and infections. IL-33 can be either on its reduced or oxidized state, which use different signaling pathways. When in its reduced state (IL33 ^{red}) it binds to IL1RL1 ((interleukin 1 receptor like 1), also named IL-33R or ST2 (receptor serum-stimulated 2). IL1RL1 exists as both a membrane bound protein or a truncated soluble form. Binding of IL-33 to IL1RL1 initiated a signaling pathway that involves NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and MAPK (mitogen-activated protein kinase), and results in release of pro-inflammatory cytokine and chemokines. The soluble form of IL1RL1 can act as a decoy receptor for IL-33. Dysregulation in the levels of IL-33 is implicated in the pathology of inflammatory and infectious diseases, including COVID-19, COPD (chronic obstructive pulmonary disease) and asthma. The involvement of IL-33 in these diseases has made it a high value therapeutic target, with strategies such as antibodies being developed to inhibit the binding of IL-33 to its receptor. One example is tozorakimab (MEDI3506), from AstraZeneca, currently being evaluated as treatment for COPD. Further studies on IL-33 and its receptor will likely result in new therapies for IL-33 related disorders.
Species:	Human
Construct:	ST2 (IL1RL1) (19-328-Fc(IgG1)-Avi)
Concentration:	1.9 mg/ml
Expression System:	HEK293
Purity:	≥90%
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate, 110 mM NaCl, 2.2 mM KCl, pH 7.4, and 20% glycerol
MW:	64 kDa + glycans
Glycosylation:	This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank Accession:	NM_016232.5
Stability:	At least 6 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Assay Conditions:	The assay was performed using a white 96-well Maxisorp plate precoated with IL-33 (#102419) at 100 ng/50 µl per well. Blocking Buffer 3 (#79743) and PBST were used for blocking and washing steps, respectively. For protein titration a serial dilution of IL1RL1 (#102451) at the highest concentration of 6 ng/µl (300 ng/reaction) was prepared in 1x PP-02 Assay Buffer (#82620). Diluted IL1RL1 was then added to the wells and plate was incubated at Room Temperature (RT) for 1 hour. The plate was then washed again and incubated with an anti-Fc-HRP conjugate (50 µl/well diluted 1000-fold in Blocking Buffer 3) was added for 1 hour at RT. After the final wash, ELISA ECL mix (Substrate A and Substrate B premixed 1:1 (#79670)) was added to each well and chemiluminescence was read.
Applications:	Useful for binding studies.

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



ST2 (IL1RL1) Binding Activity to IL-33

